Our top pick for
Building a portfolio
ACADIA Pharmaceuticals Inc is a biotechnology business based in the US. ACADIA Pharmaceuticals shares (ACAD) are listed on the NASDAQ and all prices are listed in US Dollars. ACADIA Pharmaceuticals employs 601 staff and has a trailing 12-month revenue of around USD$441.8 million.
|52-week range||USD$20.38 - USD$58.72|
|50-day moving average||USD$35.3332|
|200-day moving average||USD$45.98|
|Wall St. target price||USD$29.44|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.966|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$441.8 million|
|Gross profit TTM||USD$154.9 million|
|Return on assets TTM||-18.66%|
|Return on equity TTM||-42.47%|
|Market capitalisation||USD$3.4 billion|
TTM: trailing 12 months
There are currently 6.5 million ACADIA Pharmaceuticals shares held short by investors – that's known as ACADIA Pharmaceuticals's "short interest". This figure is 1.5% down from 6.6 million last month.
There are a few different ways that this level of interest in shorting ACADIA Pharmaceuticals shares can be evaluated.
ACADIA Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ACADIA Pharmaceuticals shares currently shorted divided by the average quantity of ACADIA Pharmaceuticals shares traded daily (recently around 3.3 million). ACADIA Pharmaceuticals's SIR currently stands at 2. In other words for every 100,000 ACADIA Pharmaceuticals shares traded daily on the market, roughly 2000 shares are currently held short.
However ACADIA Pharmaceuticals's short interest can also be evaluated against the total number of ACADIA Pharmaceuticals shares, or, against the total number of tradable ACADIA Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ACADIA Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 ACADIA Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0706% of the tradable shares (for every 100,000 tradable ACADIA Pharmaceuticals shares, roughly 71 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ACADIA Pharmaceuticals.
Find out more about how you can short ACADIA Pharmaceuticals stock.
We're not expecting ACADIA Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, ACADIA Pharmaceuticals's shares have ranged in value from as little as $20.38 up to $58.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ACADIA Pharmaceuticals's is 0.8202. This would suggest that ACADIA Pharmaceuticals's shares are less volatile than average (for this exchange).
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.